NASDAQ · ANTX
AN2 Therapeutics, Inc.
$4.69+$0.17 (+3.76%)
AN2 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.77% below the high.
Loading market information…
NASDAQ · IBIO · USD
Stock price, earnings
Quote as of Oct 29, 2026, 08:00 PM UTC. Cached market data; not a live quote.
One-year closing-price history · USD. Historical prices are not a forecast.
iBio, Inc.’s quoted price sits in the lower half of its reported 52-week range, 78.7% below the high.
52-week range
Go beyond this overview with deeper company research in PortfolioX. Explore more in the app
BEHIND THE RESULTS
iBio, Inc.’s next earnings report is currently expected on Nov 11, 2026, with estimated earnings per share of -$0.07. The reporting date and estimates may change.
Upcoming dates and analyst estimates may change. Fiscal quarters follow iBio, Inc.’s reporting calendar.
THE COMPANY BEHIND THE TICKER
iBio, Inc., a United States-based biotechnology firm, delivers contract development and manufacturing (CDMO) services to its collaborators and external clients. Its operations are structured into two distinct segments: Biopharmaceuticals and Bioprocessing. The company's leading therapeutic candidate, IBIO-100, is currently progressing through investigational new drug (IND) development, aimed at addressing systemic scleroderma and idiopathic pulmonary fibrosis. Additionally, iBio is engaged in the preclinical development of vaccine candidates, including IBIO-200 and IBIO-201, designed to prevent severe acute respiratory syndrome coronavirus 2. Another candidate, IBIO-400, is in development for the treatment of classical swine fever. Beyond its proprietary pipeline, iBio provides recombinant proteins to third parties, available both as catalog items and custom-synthesized products. It also offers comprehensive services spanning process development, advanced manufacturing, filling and finishing, and bioanalytical support. iBio maintains several strategic partnerships: a licensing agreement with Planet Biotechnology, Inc. for infectious disease therapeutics; a collaborative effort with The Texas A&M University System focused on COVID-19 vaccine candidates; a licensing pact with the University of Natural Resources and Life Sciences, Vienna; and a collaboration with CC-Pharming Ltd. Its corporate headquarters are situated in Bryan, Texas.
Latest available per-share figures in USD. The payout ratio compares dividends with earnings.
About this data · PortfolioX market data, also available in the mobile app. Prices are displayed in the listing currency; dividend amounts use the currency shown in that section. Data availability and update times vary.
Page generated Oct 30, 2026, 04:13 AM UTC. Quotes retain their own timestamp above. Missing values appear as a dash. This page is for information only, not personalized investment advice.
| Q3 2025 |
|---|
| May 2, 2025 |
| -$0.49-25.64% vs estimate |
| $0.00-100.0% vs estimate |
| Q2 2025 | Feb 10, 2025 | -$0.48-6.67% vs estimate | $200.00K+100.0% vs estimate |
|---|
| Q1 2025 | Nov 12, 2024 | -$0.46+4.17% vs estimate | $0.00 |
|---|
KEEP COMPARING
$4.69+$0.17 (+3.76%)
AN2 Therapeutics, Inc.’s quoted price sits in the upper half of its reported 52-week range, 34.77% below the high.
$15.41-$0.58 (-3.63%)
Rallybio Corporation’s quoted price sits in the upper half of its reported 52-week range, 12.31% below the high.
$2.48-$0.02 (-0.8%)
Boundless Bio, Inc.’s quoted price sits in the upper half of its reported 52-week range, 21.62% below the high.
$0.38-$0.03 (-7.1%)
Klotho Neurosciences, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.26% below the high.
$1.20-$0.03 (-2.44%)
Pluri Inc.’s quoted price sits in the lower half of its reported 52-week range, 75.36% below the high.
$3.87-$0.13 (-3.25%)
Plus Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 83.48% below the high.
$3.34-$0.04 (-1.09%)
Intensity Therapeutics, Inc.’s quoted price sits in the lower half of its reported 52-week range, 92.32% below the high.
$0.93-$0.08 (-8.04%)
Exicure, Inc.’s quoted price sits in the lower half of its reported 52-week range, 90.14% below the high.
THE ANALYST VIEW
4 ratings in the current snapshot. Strong buy and strong sell are grouped with buy and sell.
Percentages compare targets with the quoted price when currencies match. Targets are analyst estimates, not guaranteed outcomes.
Consensus coverage: 1 contributors · Median target $5.00.
Average targets in published notes for each window. These figures use a different sample from the consensus above.
HOW THE BUSINESS IS PERFORMING
Statement amounts use the company’s reporting currency and are not converted to the stock’s listing currency. K = thousand, M = million, B = billion, T = trillion. Cash-flow figures are matched by fiscal year; missing figures appear as a dash.
PUT THE NUMBERS IN CONTEXT
Current metrics alongside available historical medians. A lower multiple or higher margin alone does not establish whether a stock is a good investment.
